Spermosens (SPERM) Q4 2025 earnings summary

Executive summary

• Achieved key milestones in product development, clinical validation, and global patent approvals, focusing on transforming innovation into a market-ready diagnostic tool for male infertility.

• Completed a pivotal clinical study in June, demonstrating a correlation between JUNO binding and fertilization rates, strengthening the product's clinical value.

• Entered Memoranda of Understanding with Sapyen and RSI to advance commercialization and integration into clinical networks in the US and globally.

Financial highlights

• Operating loss for 2025 was SEK -9,201 thousand, nearly flat compared to SEK -9,163 thousand in 2024.

• Cash and cash equivalents at year-end increased to SEK 6,836 thousand from SEK 659 thousand the previous year.

• Equity at period end rose to SEK 32,411 thousand from SEK 27,345 thousand year-over-year.

• Total cash flow for the year was SEK 6,177 thousand, up from SEK -3,833 thousand in 2024.

Outlook and guidance

• Generation 3 system development is on track, with completion and validation targeted for the first half of 2026.

• Focus remains on technical and clinical validation to meet commercialization requirements and integration into fertility workflows.

• Ongoing efforts to convert partnership frameworks into formal commercial agreements.